Loading stock data…
SNY
$44.73+0.85 (+1.94%)
After Hours$44.73+0.00 (+0.00%)· Last close Jun 9
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at $44.73. Wall Street consensus targets $55.90 (9 analysts), implying a +25.0% move over the next 12 months. The stock is currently 15% below its 52-week high of $52.68, remaining 1.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +25.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$44.73
Potential Downside
0%
Whystock Fair Value$44.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$55.90+25.0%
Range$51.00 – $63.00
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
5.41%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.38%
Volume
Today's trading volume
2.74M
Recent News
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
European Stocks Little Changed in Monday Trading; Middle East Fight Resumes Over Weekend
The European stock markets were little changed in Monday trading as Middle East hostilities resumed
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M
Sanofi and Owkin partner to develop next-generation biopharma AI agents
The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery.
Sanofi Owkin AI Deal Puts R&D Shift And Valuation In Focus
Sanofi (ENXTPA:SAN) has entered a multi year collaboration with Owkin to co develop AI driven biopharma agents for drug research and development. The agreement includes licensing Owkin's K Pro AI Scientist platform to support autonomous, complex tasks across the drug development lifecycle. The partnership is focused on applying agentic AI systems to accelerate discovery and improve decision making in Sanofi's R&D operations. For investors watching ENXTPA:SAN, this AI partnership arrives as...